Rockin' the Status Quo 💥️ A groundbreaking drug for HIV prevention hits the US market
Approval granted in U.S. for novel HIV prevention medication
🔗 Facebook 🔗 Twitter 🔗 Whatsapp 📧 E-Mail 📝 Print 📏 Copy Link
🔔 Sound the Alarm!🔔 The war against AIDS just got a massive boost! On Wednesday, the U.S. Food and Drug Administration (FDA) approved the new drug Lenacapavir, developed by Gilead Sciences. With stellar results demonstrating a protection rate of 99.9% against HIV, Lenacapavir is the talk of the town. Unlike traditional HIV drugs, this superstar requires only two injections per year!
Gilead CEO, Daniel O'Day, couldn't hold back his excitement: "This is a historic day in the ongoing battle against HIV."
In scientific trials involving over 4,000 participants, only two individuals developed the virus after taking Lenacapavir. However, the edge of victory comes at a price. With an estimated cost of $28,000 (roughly €24,000) per person annually, some experts think the drug could break the bank. Experts suspect production costs to be around $40, but it remains to be seen if the drug prices will actually drop.
Gilead pledged in October 2024 to work with six generic manufacturers to make Lenacapavir available to low-income countries—but not without some criticism. Detractors voice concerns that millions of HIV patients worldwide will continue to suffer due to high costs and lack of access.
For up-to-the-minute updates on Lenacapavir in low-income countries, keep an eye on announcements from the drug manufacturer and global health organizations.
The new HIV prevention drug Lenacapavir, developed by Gilead Sciences, has been approved by the U.S. Food and Drug Administration (FDA), and its employment policy for pricing might attract scrutiny within the community, particularly on mental-health issues related to health-and-wellness and nutrition, as its annual cost of $28,000 (roughly €24,000) could be overwhelming for many patients. In line with this, it would be interesting to see if there will be policy changes to make Lenacapavir accessible to a broader demographic, ensuring equitable access, especially in low-income countries.
